Civilization Ventures

Civilization Ventures is a venture capital firm founded in 2017, focusing on early-stage investments in health tech and biology sectors. The firm primarily invests in genomics, diagnostics, digital health, and synthetic biology, aiming to support visionary founders addressing critical challenges in these fields. With over $100 million in assets under management, Civilization Ventures has partnered with more than 60 innovative companies across the United States.

The firm's investment strategy emphasizes a 'mentor capital' approach, providing founders with the resources and guidance needed to succeed without replacing them. This approach leverages an extensive network of life science leaders, academics, and clinicians to identify and support leading innovations. Civilization Ventures also runs a Fellowship program to train PhDs and MDs to become future entrepreneurs in the life sciences sector.

Notable investments include Rocket Pharma, a gene therapy leader listed on Nasdaq, and Singular Bio, acquired by Invitae. The firm's portfolio also features companies like Lemonaid Health, acquired by 23andMe, and Rewrite, acquired by Intellia. These exits highlight Civilization Ventures' commitment to backing companies that advance human longevity and address significant health challenges.